Basel, Switzerland, 15 February 2011 – EVA Pharma and Lonza announced today that they have signed a multi-year supply agreement for Carnipure™ tartrate and Carnipure™ crystalline, two of Lonza’s L-Carnitine products, as well as a Carnipure™ brand licensing agreement. The signing of these contracts will further strengthen the collaboration between both companies.
“Thanks to Lonza’s continuous support, we have been able to establish Carnivita Forte as one of our best-selling products in the field of urology,” comments Dr. Riad Armanious, CEO of EVA Pharma. Carnivita Forte is an over-the-counter product meant for men wishing to promote their fertility by increasing sperm count and sperm motility. The product contains 1 g Carnipure™ tartrate per tablet.
L-Carnitine is a nutrient that plays an important role in fat and energy metabolism. It is produced in the body and can be found in some dietary sources, mostly of animal origin. L-Carnitine transports long-chain fatty acids into the cells’ mitochondria, where they are transformed into energy. Organs and cells with high energy demands, such as sperm, contain high levels of LCarnitine upon which they depend for normal functionality.
“Extensive research shows that Carnipure™ supplementation may positively influence sperm quality or, more specifically, sperm count, sperm motility and the number of motile sperm, thus playing an important part in male fertility,” comments Ulla Freitas, Nutrition Science Team Leader at Lonza.
Lonza is the world’s leading producer of L-Carnitine. Under the Carnipure™ brand, Lonza offers Carnipure™ crystalline, which is pure L-Carnitine, as well as Carnipure™ tartrate, a nonhygroscopic form made of L-Carnitine and tartaric acid. Products displaying the Carnipure™ quality seal on the packaging show the consumer that they contain pure L-Carnitine from Lonza.
About EVA Pharma
Established in 1997, Eva Pharma is one of Egypt’s leading pharmaceutical companies, built on the heritage of Les Laboratoires Delta, Egypt’s second oldest pharmaceutical company. Today, Eva Pharma is the fastest growing pharmaceutical company in the MENA region, growing at a rate of more than 50% CAGR (compound annual growth rate) for the past seven years; transforming from a successful local company into a world class multinational organization, with sales and marketing presence across the region. Eva Pharma is an active contributor to the on-going drug industry in Egypt, North Africa and the Middle East, with huge market participation. Currently, Eva Pharma consists of a team of 1,500 loyal staff and produces on average 300,000 effective and affordable packs of medicine daily from 102 different products. All products are stamped by several recognized quality seals and the Eva Pharma logo - which, due to exacting quality standards, acts as a stamp of approval.
Eva Pharma is now one of the top five manufacturing pharmaceutical companies in Egypt according to IMS (MAT11/2010) www.evapharma.com